NASDAQ:TPTX - Turning Point Therapeutics Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $88.86
  • Forecasted Upside: 142.18 %
  • Number of Analysts: 9
  • Breakdown:
  • 0 Sell Ratings
  • 2 Hold Ratings
  • 7 Buy Ratings
  • 0 Strong Buy Ratings
$36.69
▼ -0.05 (-0.14%)

This chart shows the closing price for TPTX by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Turning Point Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TPTX and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TPTX

Analyst Price Target is $88.86
▲ +142.18% Upside Potential
This price target is based on 9 analysts offering 12 month price targets for Turning Point Therapeutics in the last 3 months. The average price target is $88.86, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 142.18% upside from the last price of $36.69.

This chart shows the closing price for TPTX for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 9 investment analysts is to buy stock in Turning Point Therapeutics. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
2/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
5/28/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 1 hold ratings
  • 0 sell ratings
8/26/2021
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
11/24/2021
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
2/22/2022
  • 0 strong buy ratings
  • 6 buy ratings
  • 2 hold ratings
  • 0 sell ratings
4/23/2022
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings
5/23/2022

Latest Recommendations

  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/20/2022Bank of AmericaInitiated CoverageBuy$58.00Medium
5/11/2022WedbushLower Price Target$93.00 ➝ $61.00High
3/22/2022HC WainwrightLower Price TargetBuy$162.00 ➝ $161.00High
3/1/2022Stifel NicolausLower Price TargetHold$50.00 ➝ $45.00Low
2/10/2022Wells Fargo & CompanyLower Price TargetOverweight$120.00 ➝ $85.00High
2/8/2022SVB LeerinkReiterated RatingOutperformHigh
1/21/2022OppenheimerLower Price TargetOutperform$115.00 ➝ $105.00Low
1/3/2022GuggenheimLower Price Target$118.00 ➝ $107.00High
12/6/2021CowenInitiated CoverageOutperformHigh
11/10/2021OppenheimerLower Price TargetFair Value ➝ Outperform$150.00 ➝ $115.00Medium
10/12/2021HC WainwrightLower Price TargetBuy$178.00 ➝ $162.00Low
10/11/2021JMP SecuritiesDowngradeOutperform ➝ Market PerformMedium
10/10/2021SVB LeerinkReiterated RatingBuyHigh
10/8/2021WedbushLower Price TargetOutperform$166.00 ➝ $125.00Low
10/7/2021Wells Fargo & CompanyLower Price TargetOverweight$160.00 ➝ $120.00Medium
9/29/2021Stifel NicolausInitiated CoverageHold$75.00High
8/10/2021HC WainwrightReiterated RatingBuy$178.00High
4/13/2021HC WainwrightLower Price TargetBuy$190.00 ➝ $186.00Low
4/6/2021Roth CapitalBoost Price TargetBuy$170.00 ➝ $175.00High
4/6/2021HC WainwrightLower Price TargetBuy$190.00 ➝ $186.00High
4/6/2021OppenheimerReiterated RatingBuy$150.00High
1/29/2021Roth CapitalBoost Price Target$140.00 ➝ $170.00Low
1/19/2021HC WainwrightBoost Price TargetBuy$130.00 ➝ $190.00Medium
1/12/2021JMP SecuritiesBoost Price Target$125.00 ➝ $160.00Medium
1/12/2021OppenheimerBoost Price TargetOutperform$130.00 ➝ $150.00Medium
12/14/2020SVB LeerinkBoost Price TargetOutperform$116.00 ➝ $127.00High
12/8/2020Roth CapitalBoost Price Target$133.00 ➝ $140.00Medium
12/8/2020JMP SecuritiesInitiated CoverageOutperform$125.00High
11/13/2020OppenheimerBoost Price TargetOutperform$120.00 ➝ $130.00Medium
10/30/2020Roth CapitalBoost Price TargetBuy$77.00 ➝ $133.00Medium
10/26/2020Wells Fargo & CompanyBoost Price TargetOverweight$88.00 ➝ $133.00High
10/26/2020HC WainwrightBoost Price TargetBuy$100.00 ➝ $130.00High
10/26/2020SVB LeerinkBoost Price TargetOutperform$77.00 ➝ $116.00High
10/25/2020OppenheimerBoost Price TargetOutperform$90.00 ➝ $120.00High
9/21/2020HC WainwrightReiterated RatingBuy$88.00 ➝ $100.00High
8/19/2020Roth CapitalReiterated RatingPositive ➝ Buy$75.00 ➝ $77.00High
7/14/2020HC WainwrightReiterated RatingBuy$88.00High
7/9/2020OppenheimerInitiated CoverageOutperform$90.00Low
6/23/2020HC WainwrightReiterated RatingBuy$88.00High
5/26/2020HC WainwrightBoost Price TargetBuy$72.00 ➝ $88.00High
5/14/2020Roth CapitalBoost Price TargetPositive ➝ Buy$65.00 ➝ $75.00High
5/13/2020Wells Fargo & CompanyBoost Price TargetOverweight$62.00 ➝ $76.00High
5/13/2020SVB LeerinkBoost Price TargetOutperform$60.00 ➝ $67.00High
3/17/2020HC WainwrightBoost Price TargetBuy$70.00 ➝ $72.00High
1/21/2020HC WainwrightReiterated RatingBuy$70.00Medium
12/10/2019HC WainwrightReiterated RatingBuy$70.00Medium
11/25/2019HC WainwrightReiterated RatingBuy$70.00High
11/14/2019Roth CapitalInitiated CoverageBuy$65.00Medium
11/12/2019HC WainwrightReiterated RatingBuy$70.00Medium
9/25/2019HC WainwrightInitiated CoverageBuy$70.00Medium
9/9/2019WedbushInitiated CoverageOutperform$63.00Low
9/4/2019Wells Fargo & CompanyBoost Price TargetOutperform$53.00 ➝ $62.00High
7/24/2019GuggenheimInitiated CoverageBuy ➝ Buy$58.00Medium
5/13/2019Royal Bank of CanadaInitiated CoverageOutperform ➝ Outperform$48.00High
5/13/2019The Goldman Sachs GroupInitiated CoverageBuy ➝ Buy$50.00High
5/13/2019Wells Fargo & CompanyInitiated CoverageOutperform ➝ Outperform$53.00High
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.09 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 5 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/26/2021
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
11/25/2021
  • 0 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 3 very negative mentions
12/25/2021
  • 2 very positive mentions
  • 5 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
1/24/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/23/2022
  • 2 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
3/25/2022
  • 3 very positive mentions
  • 1 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
4/24/2022
  • 1 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
5/24/2022

Current Sentiment

  • 1 very positive mentions
  • 22 positive mentions
  • 2 negative mentions
  • 2 very negative mentions
Turning Point Therapeutics logo
Turning Point Therapeutics, Inc., a clinical-stage precision oncology biopharmaceutical company, engages in designing and developing therapies that target genetic drivers of cancer. It develops a pipeline of tyrosine kinase inhibitors (TKIs) that targets genetic drivers of cancer in TKI-naïve and TKI-pretreated patients. The company's lead drug candidate repotrectinib is being evaluated in an ongoing Phase 1/2 trial called TRIDENT-1 for the treatment of patients with ROS1+ advanced non-small-cell lung cancer (NSCLC) and patients with ROS1+ and NTRK+ advanced solid tumors. It also develops TPX-0022, a MET/SRC/CSF1R inhibitor, which is in Phase 1 SHIELD-1 clinical trial for patients with advanced solid tumors harboring genetic alterations in MET; TPX-0046, a RET inhibitor that is in 1/2 SWORD-1 clinical trial for patients with advanced solid tumors harboring RET genetic alterations; and TPX-0131, an ALK inhibitor, which is in Phase 1/2 FORGE-1 study for patient with advanced or metastatic TKI-pretreated ALK-positive NSCLC. Turning Point Therapeutics, Inc. was founded in 2013 and is headquartered in San Diego, California.
Read More

Today's Range

Now: $36.69
Low: $36.04
High: $37.75

50 Day Range

MA: $30.03
Low: $24.32
High: $36.74

52 Week Range

Now: $36.69
Low: $23.77
High: $83.06

Volume

545,710 shs

Average Volume

592,504 shs

Market Capitalization

$1.82 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.86

Frequently Asked Questions

What sell-side analysts currently cover shares of Turning Point Therapeutics?

The following Wall Street sell-side analysts have issued reports on Turning Point Therapeutics in the last twelve months: Bank of America Co., Cowen Inc, Guggenheim, HC Wainwright, JMP Securities, Oppenheimer Holdings Inc., Stifel Nicolaus, SVB Leerink LLC, Wedbush, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for TPTX.

What is the current price target for Turning Point Therapeutics?

0 Wall Street analysts have set twelve-month price targets for Turning Point Therapeutics in the last year. Their average twelve-month price target is $88.86, suggesting a possible upside of 142.2%.
View the latest price targets for TPTX.

What is the current consensus analyst rating for Turning Point Therapeutics?

Turning Point Therapeutics currently has 2 hold ratings and 7 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe TPTX will outperform the market and that investors should add to their positions of Turning Point Therapeutics.
View the latest ratings for TPTX.

How do I contact Turning Point Therapeutics' investor relations team?

Turning Point Therapeutics' physical mailing address is 10628 SCIENCE CENTER DRIVE SUITE 225, SAN DIEGO CA, 92121. The company's listed phone number is (858) 926-5251 and its investor relations email address is [email protected] The official website for Turning Point Therapeutics is www.tptherapeutics.com. Learn More about contacing Turning Point Therapeutics investor relations.